Patents in the Cannabis Industry: Increased Investor Protection
May 5th, 2021
App, Exclusive, News, Top Story
In any emerging industry, patent protection becomes a key component. The ability to exclusively produce and profit off of one’s own innovation encourages research, development, and investment. Many companies’ valuations are based in a large part on the extent to which their intellectual property is protected. The cannabis industry offers some hurdles to achieving that sort of protection, among them is the fact the plant is federally illegal, and that many cannabis species are naturally occurring which makes them difficult to patent. There are however companies that have been able to be successful at protecting their assets. Utility patents, covering a novel invention that is new and useful, offer perhaps the best path to intellectual property protection in the cannabis industry.
One company, Ovation Science Inc. (CSE: OVAT) (OTCQB: OVATF), holds utility and product patents around its Invisicare® drug delivery technology for cannabinoids. The proprietary delivery platform greatly enhances the deliverability of cannabinoids through topical and transdermal means, like creams, and lotions. With wellness and beauty markets comprising one of the fastest-growing segments in the cannabis industry, it might be worth taking a look at what Ovation Science has to offer.
Ovation’s patents covering Invisicare® include composition, the manufacturing process, and use. In essence, nobody can utilize the unique delivery system in any way without Ovation’s consent. Not only is the underlying technology protected, but the company has the ability to patent individual products that have been developed using Invisicare®. To this point, the company has developed 30 patent-protected products using CBD or THC as active ingredients. For example, Ovation’s CBD sunscreen is protected through 2029. Even without a specific product patent, all of Ovation’s products utilize Invisicare® technology and are therefore protected by the technology’s patent. Furthermore, Ovation has a patent-pending in the US and Canada for its transdermal cannabinoid formulations. When granted, this patent would further protect Ovation’s transdermal products for 20 years.
Not only are Ovation’s patents broadly protective of its products and technology, but they are also also geographically distributed across the globe. Invisicare® is patented in the US, Canada, four European countries, China, India, Australia, Hong Kong, and South Korea.
Click here to learn more about investing in patented skincare technology
As opposed to patents based on unique strains of cannabis or hemp, Ovation patents are fairly easy and practical to enforce. With plants, it can be difficult to prove that the genetics of a strain are exactly the same as the patented one. Additionally, plant patents are tough to get and offer limited protection in practice. They are often used for show, to impress investors and potential clients, but rarely are enforced. Ovation’s delivery technology is built using closely guarded trade secrets that results in products with unique and easily identifiable characteristics. The company completely controls the production processes and sells its Invisicare® polymer technology to its licensees as part of its out-licensing model; always protecting its “secret sauce” so that duplication of Invisicare benefits are not possible.
Highly Effective Delivery
Cannabinoids are lipophilic (soluble in fat) and hydrophobic (insoluble in water). Using hydrophilic and hydrophobic polymers, Invisicare® technology bonds active ingredients to the skin for up to four hours and forms a barrier that resists wash off and perspiration. Additionally, Invisicare increases the release of ingredients to and through the skin. In its own research, the company found that Invisicare® CBD formulations exhibited a 40% topical release compared to just 3% for market-leading formulations after a two-hour period.
In addition, the company’s research found that its transdermal CBD formula—designed to be absorbed through the skin to provide systemic effects—powered by Invisicare® had a greater than 80% penetrate rate at six hours compared to 10% to 25% for market-leading formulas. These improvements translate to more active ingredients delivered to target sites and represent a major competitive advantage for products utilizing the technology.
Ovation creates its own products, sold to the health and wellness sector through the InvibeMD portal and to the beauty and skincare sector through the ArloCBDBeauty portal. Aside from direct to consumer sales through the portals, a major part of its revenue plan comes from licensing agreements with cannabis companies already distributing and selling products in key markets where cannabis is approved. Ovation’s first US licensing agreement is in Nevada. The company is currently seeking and developing agreements with licensed operators in other states and countries as well.
Revenues from licensing arrangements range from product development fees, licensing fees, recurring royalties based on sales, and the sale of Invisicare® polymers to its licensees. The company envisions reproducing this same model through-out the US and in international markets as well, where legally approved.
Backed by the strength of its intellectual property protection, Ovation Science is primed to enter key markets with its groundbreaking cannabinoid products powered by its delivery technology. Look for further expansion over the coming quarters as the company brings Invisicare®-powered goods to consumers and licensees looking for effective products that deliver on the promise of cannabinoid science.
Click here to learn more about investing in patented skincare technology
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.